Skip to main content

Market Overview

DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke

Share:
DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke
  • The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or KLK1) for the treatment of patients with Acute Ischemic Stroke (AIS).
  • The upcoming pivotal ReMEDy2 trial will evaluate whether DM199 can improve three-month outcomes in AIS patients without other treatment options. It will enroll approximately 350 participants.
  • Endpoints will include the modified Rankin Scale, stroke recurrence, the National Institute of Health Stroke Score, Barthel Index, deaths, safety, and tolerability.
  • DiaMedica will remain blinded to the data in the interim.
  • Price Action: DMAC shares are up 6.9% at $6.95 on the last check Monday.
 

Related Articles (DMAC)

View Comments and Join the Discussion!

Posted-In: Briefs Investigational New Drug Application StrokesBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com